Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Behaviors and Mental Disorders

Heart and Blood Diseases

Diabetes Mellitus

Depressive Disorder

Depressive Disorder, Major

Depression

Hypertension

Behavioral Symptoms

Mood Disorders

Mental Disorders

Psychotic Disorders

Psychotropic Drugs

All Drugs and Chemicals

Vasoconstrictor Agents

Other Dietary Supplements

Desvenlafaxine Succinate

Norepinephrine

Serotonin

Serotonin and Noradrenaline Reuptake Inhibitors

Neurotransmitter Agents

Antidepressive Agents

Omega 3 Fatty Acid

Desvenlafaxine 50mg/day \& Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period

Desvenlafaxine 50mg/day \& Placebo (for Omega 3 FA supplement) over a 12 week period

Desvenlafaxine

Omega 3 Fatty acids

Placebo (for Omega 3 fatty acid supplement)

Jayesh Kamath, MD PhD

To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.

Hospital Anxiety and Depression Scale: This is a validated scale for measuring depression/anxiety symptoms in patients with medical conditions.

UConn Health

Desvenlafaxine 50mg/day \& Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period

Desvenlafaxine

Omega 3 Fatty acids

2 subjects were randomized to this group

Desvenlafaxine + Omega 3 FA Supplement

Desvenlafaxine 50mg/day \& Placebo (for Omega 3 FA supplement) over a 12 week period

Desvenlafaxine

Placebo (for Omega 3 fatty acid supplement)

3 subjects were randomized to this group

Desvenlafaxine + Placebo (for Omega 3 FA Supplement)

Desvenlafaxine 50mg/day \& Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period

Desvenlafaxine

Omega 3 Fatty acids

Age range: 53 to 66 years Gender: 1 male and 1 female

Desvenlafaxine 50mg/day \& Placebo (for Omega 3 FA supplement) over a 12 week period

Desvenlafaxine

Placebo (for Omega 3 fatty acid supplement) Age range: 53 to 66 years \] Gender: 1 male and 2 females

Total

Age, Categorical

Sex: Female, Male

White Non-Hispanic/Latino

Race/Ethnicity, Customized

United States

Region of Enrollment

Due to very low enrollment in both arms, only descriptive analyses was completed for both arms

Jayesh Kamath MD PhD

Desvenlafaxine 50mg/day \& Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period

Desvenlafaxine

Omega 3 Fatty acids

Desvenlafaxine 50mg/day \& Placebo (for Omega 3 FA supplement) over a 12 week period

Desvenlafaxine

Placebo (for Omega 3 fatty acid supplement)

Planned statistical analyses were not performed due to lack of adequate sample size. The data collected were not intended to be summarized if there were fewer than 10 participants.

Spots Global Cancer Trial Database for desvenlafaxine